After Ascendis Pharma announced the FDA has extended the TransCon PTH review period by three months and pushed out the prescription drug user fee act ,or PDUFA, action date to August 14, BofA caught up with management, who said that the FDA has not made any additional requests from the company at this time. The firm, which notes that PDUFA extensions are not uncommon with the FDA, continues to believe that a U.S. approval is likely and maintains a Buy rating and $165 price target on Ascendis shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- FDA Delays Ascendis Pharma’s Drug Review
- Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
- Ascendis announces 2-year results from post-hoc analysis of Phase 3 trial
- Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
- Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024